Reed Johnson

477 total citations
13 papers, 370 citations indexed

About

Reed Johnson is a scholar working on Neurology, Cognitive Neuroscience and Psychiatry and Mental health. According to data from OpenAlex, Reed Johnson has authored 13 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Neurology, 5 papers in Cognitive Neuroscience and 5 papers in Psychiatry and Mental health. Recurrent topics in Reed Johnson's work include Parkinson's Disease Mechanisms and Treatments (10 papers), Neurological disorders and treatments (7 papers) and Autism Spectrum Disorder Research (5 papers). Reed Johnson is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (10 papers), Neurological disorders and treatments (7 papers) and Autism Spectrum Disorder Research (5 papers). Reed Johnson collaborates with scholars based in United States, Germany and Canada. Reed Johnson's co-authors include Rajesh Pahwa, Robert A. Hauser, Stuart Isaacson, Caroline M. Tanner, Mary Jean Stempien, Daniel Truong, Rajiv Patni, Pinky Agarwal, Paul A. Nausieda and Kelly E. Lyons and has published in prestigious journals such as Neurology, Clinical Pharmacokinetics and JAMA Neurology.

In The Last Decade

Reed Johnson

13 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Reed Johnson United States	10	298	128	57	51	27	13	370
Marcelo Merello Argentina	10	269 0.9×	135 1.1×	52 0.9×	35 0.7×	32 1.2×	17	349
Denise Hack Nicaretta Brazil	13	268 0.9×	72 0.6×	43 0.8×	34 0.7×	41 1.5×	33	360
I Gemende Germany	6	238 0.8×	79 0.6×	39 0.7×	25 0.5×	13 0.5×	7	303
Th. M�ller Germany	9	232 0.8×	90 0.7×	79 1.4×	32 0.6×	44 1.6×	10	348
Mubasher A. Qamar United Kingdom	11	339 1.1×	87 0.7×	69 1.2×	32 0.6×	35 1.3×	24	409
Guanglu Li China	9	226 0.8×	73 0.6×	66 1.2×	26 0.5×	71 2.6×	16	368
A. Castro Spain	8	194 0.7×	54 0.4×	24 0.4×	28 0.5×	14 0.5×	13	236
Samuel D. Kim Australia	8	279 0.9×	58 0.5×	24 0.4×	103 2.0×	31 1.1×	10	350
Paola Stirpe Italy	10	338 1.1×	120 0.9×	42 0.7×	36 0.7×	24 0.9×	12	403
Matteo Costanzo Italy	14	355 1.2×	120 0.9×	56 1.0×	34 0.7×	46 1.7×	38	483

Countries citing papers authored by Reed Johnson

Since Specialization

Citations

This map shows the geographic impact of Reed Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Reed Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Reed Johnson more than expected).

Fields of papers citing papers by Reed Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Reed Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Reed Johnson. The network helps show where Reed Johnson may publish in the future.

Co-authorship network of co-authors of Reed Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Reed Johnson. A scholar is included among the top collaborators of Reed Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Reed Johnson. Reed Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Pahwa, Rajesh, Susan H. Fox, Robert A. Hauser, et al.. (2022). Clinically important change on the Unified Dyskinesia Rating Scale among patients with Parkinson's disease experiencing dyskinesia. Frontiers in Neurology. 13. 846126–846126. 6 indexed citations

Cohen, Jeffrey A., Michelle Cameron, Myla Goldman, et al.. (2021). A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal. 28(5). 817–830. 3 indexed citations

Mehta, Shyamal H., Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, & Reed Johnson. (2021). Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia. Neurology and Therapy. 10(1). 307–320. 14 indexed citations

Tanner, Caroline M., Rajesh Pahwa, Robert A. Hauser, et al.. (2020). EASE LID 2: A 2-Year Open-Label Trial of Gocovri (Amantadine) Extended Release for Dyskinesia in Parkinson’s Disease. Journal of Parkinson s Disease. 10(2). 543–558. 25 indexed citations

Hauser, Robert A., Daniel Kremens, Lawrence Elmer, et al.. (2019). Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials. Journal of Parkinson s Disease. 9(3). 591–600. 14 indexed citations

Isaacson, Stuart, Stanley Fahn, Rajesh Pahwa, et al.. (2018). Parkinson's Patients with Dyskinesia Switched from Immediate Release Amantadine to Open‐label ADS‐5102. Movement Disorders Clinical Practice. 5(2). 183–190. 13 indexed citations

Elmer, Lawrence, Jorge L. Juncos, Carlos Singer, et al.. (2018). Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease. CNS Drugs. 32(4). 387–398. 47 indexed citations

Pahwa, Rajesh, Caroline M. Tanner, Robert A. Hauser, et al.. (2018). A Clinically Important Difference (CID) for the Unified Dyskinesia Rating Scale (UDysRS) Total Score Change in Parkinson’s Disease (PD) Patients with Dyskinesia (P2.052). Neurology. 90(15_supplement). 2 indexed citations

Hauser, Robert A., Rajesh Pahwa, William A. Wargin, et al.. (2018). Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia. Clinical Pharmacokinetics. 58(1). 77–88. 36 indexed citations

10.

Pahwa, Rajesh, Stuart Isaacson, Joohi Jimenez‐Shahed, et al.. (2018). Impact of dyskinesia on activities of daily living in Parkinson's disease: Results from pooled phase 3 ADS-5102 clinical trials. Parkinsonism & Related Disorders. 60. 118–125. 21 indexed citations

11.

Hauser, Robert A., Rajesh Pahwa, Caroline M. Tanner, et al.. (2017). ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson’s Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study. Journal of Parkinson s Disease. 7(3). 511–522. 40 indexed citations

12.

Pahwa, Rajesh, Caroline M. Tanner, Robert A. Hauser, et al.. (2017). ADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study). JAMA Neurology. 74(8). 941–941. 134 indexed citations

13.

Wells, Brian, et al.. (1991). A placebo-controlled trial of nadolol in the treatment of neuroleptic-induced akathisia.. PubMed. 52(6). 255–60. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact